Literature DB >> 23324825

Intestinal proteome changes during infant necrotizing enterocolitis.

Pingping Jiang1, Birgitte Smith, Niels Qvist, Christian Nielsen, Jennifer Man-Fan Wan, Wai-Hung Sit, Tim Kåre Jensen, Hualin Wang, Per Torp Sangild.   

Abstract

BACKGROUND: Changes in the intestinal and colonic proteome in patients with necrotizing enterocolitis (NEC) may help to characterize the disease pathology and identify new biomarkers and treatment targets for NEC.
METHODS: Using gel-based proteomics, proteins in NEC-affected intestinal and colonic sections were compared with those in adjacent, near-normal tissue sections within the same patients. Western blot and immunohistochemistry were applied to crossvalidate proteomic data and histological location of some selected proteins.
RESULTS: Thirty proteins were identified with differential expression between necrotic and vital small-intestine sections and 23 proteins were identified for colon sections. Five proteins were similarly affected in the small intestine and colon: histamine receptors (HRs), actins, globins, immunoglobulin, and antitrypsin. Two heat shock proteins (HSPs) were affected in the small intestine. Furthermore, proteins involved in antioxidation, angiogenesis, cytoskeleton formation, and metabolism were affected. Finally, secretory proteins such as antitrypsin, fatty-acid binding protein 5, and haptoglobin differed between NEC-affected and vital tissues.
CONCLUSION: NEC progression affects different pathways in the small intestine and colon. HSPs may play an important role, especially in the small intestine. The identified secretory proteins should be investigated as possible circulating markers of NEC progression in different gut regions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23324825     DOI: 10.1038/pr.2012.182

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Invited review: the preterm pig as a model in pediatric gastroenterology.

Authors:  P T Sangild; T Thymann; M Schmidt; B Stoll; D G Burrin; R K Buddington
Journal:  J Anim Sci       Date:  2013-08-13       Impact factor: 3.159

2.  Metaproteomics reveals functional differences in intestinal microbiota development of preterm infants.

Authors:  Romy D Zwittink; Diny van Zoeren-Grobben; Rocio Martin; Richard A van Lingen; Liesbeth J Groot Jebbink; Sjef Boeren; Ingrid B Renes; Ruurd M van Elburg; Clara Belzer; Jan Knol
Journal:  Mol Cell Proteomics       Date:  2017-07-06       Impact factor: 5.911

Review 3.  The Microbiome and Biomarkers for Necrotizing Enterocolitis: Are We Any Closer to Prediction?

Authors:  Brigida Rusconi; Misty Good; Barbara B Warner
Journal:  J Pediatr       Date:  2017-06-29       Impact factor: 4.406

Review 4.  The science and necessity of using animal models in the study of necrotizing enterocolitis.

Authors:  Guillermo J Ares; Steven J McElroy; Catherine J Hunter
Journal:  Semin Pediatr Surg       Date:  2017-11-06       Impact factor: 2.754

5.  Protective effects of transforming growth factor β2 in intestinal epithelial cells by regulation of proteins associated with stress and endotoxin responses.

Authors:  Duc Ninh Nguyen; Pingping Jiang; Susanne Jacobsen; Per T Sangild; Emøke Bendixen; Dereck E W Chatterton
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

6.  Proteomics Profiling of Stool Samples from Preterm Neonates with SWATH/DIA Mass Spectrometry for Predicting Necrotizing Enterocolitis.

Authors:  David Gagné; Elmira Shajari; Marie-Pier Thibault; Jean-François Noël; François-Michel Boisvert; Corentin Babakissa; Emile Levy; Hugo Gagnon; Marie A Brunet; David Grynspan; Emanuela Ferretti; Valérie Bertelle; Jean-François Beaulieu
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

7.  Zonulin: A Potential Marker of Intestine Injury in Newborns.

Authors:  Anna Tarko; Anna Suchojad; Marta Michalec; Małgorzata Majcherczyk; Aniceta Brzozowska; Iwona Maruniak-Chudek
Journal:  Dis Markers       Date:  2017-07-09       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.